CEO SUMMARY: Wall Street likes the potential of molecular diagnostics to infuse new revenues and operating profits into the laboratory industry. That is one reason Quest Diagnostics Incorporated and Laboratory Corporation of America are assertively seeking exclusive access to new molecular technologies. The latest such deal is Quest Diagnostics’ $42.8 million agreement with Ciphergen Biosystems. […]
For Quest and LabCorp, The Story is “Molecular”
Both lab companies racing to lock up most promising molecular technologies
- By Robert Michel
- > From the Volume XII No. 11 - August 1, 2005 Issue
- Tags: blood brothers, cap, clinical testing, diagnostic assays, Diagnostic technology, Diagnostic tests, hie, hospital laboratory, hospital laboratory outreach, lab acquisition, lab test, laboratories, laboratory company, laboratory industry, laboratory outreach, laboratory outreach program, Medicare, molecular assay, molecular assays, molecular diagnostic, molecular testing, new diagnostic technology, quality system, quality systems, quest diagnostics and labcorp, roche diagnostic, roche diagnostics, Six Sigma, six sigma quality, the laboratory
